Biomimetic and Bioinspired Intervention Strategies for the Treatment of Rheumatoid Arthritis
Source abstract
Abstract
Abstract Rheumatoid arthritis (RA) affects the joints and extra‐articular organs and poses a significant health care problem in the modern era. Although current standard treatment modalities successfully control RA flares, no curative treatment modality for RA has been developed. Nanomedicines have addressed the drug side effects and limited efficacy of RA treatment. However, synthetic nanoparticles (NPs) can be toxic and induce immune responses in vivo, posing a risk of further RA progression. Biomimetic nanodrug delivery systems have the potential to improve the biocompatibility of synthetic NPs and the stability and targeting of pharmaceuticals in vivo. For many immune‐related diseases with a complex pathogenesis and that involve a large number of different cell types, biomimetic nanodelivery systems can reduce the immunogenicity of NPs. Furthermore, some bioinspired strategies can mimic certain components of the pathological process, allowing for a more precise drug delivery and effective disease control via the carriers. This article highlights recent research on biomimetic nanodelivery systems for the treatment of RA and categorizes the design methodologies for various targets and carriers.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Rheumatoid Arthritis Research and Therapies · Autoimmune and Inflammatory Disorders Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Orthopedic The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052 China
Department of Magnetic Resonance Imaging The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052 China
References (100+)
Show source-provided references
1. 10.1001/jama.2018.1310310.1001/jama.2018.13103 ↗
2. Hazlewood G. S. · Cochrane Database Syst. Rev. · 2016 · 2016 · CD010227
3. Hazlewood G. S. · BMJ · 2016 · 353
4. 10.1136/annrheumdis-2019-21665510.1136/annrheumdis-2019-216655 ↗
5. 10.1038/s41577-019-0178-810.1038/s41577-019-0178-8 ↗
6. 10.1136/ard.2007.07197710.1136/ard.2007.071977 ↗
7. 10.1016/j.jconrel.2019.12.02510.1016/j.jconrel.2019.12.025 ↗
8. 10.1016/j.molmed.2018.12.00810.1016/j.molmed.2018.12.008 ↗
9. 10.1021/acsami.8b2269310.1021/acsami.8b22693 ↗
10. 10.1093/rheumatology/kez28610.1093/rheumatology/kez286 ↗
11. 10.1111/1756-185X.1368810.1111/1756-185X.13688 ↗
12. 10.1136/ard.2010.13869310.1136/ard.2010.138693 ↗
13. 10.1097/00003086-200110001-0000410.1097/00003086-200110001-00004 ↗
14. 10.1038/s41584-018-0033-510.1038/s41584-018-0033-5 ↗
15. 10.1016/j.actbio.2019.10.00310.1016/j.actbio.2019.10.003 ↗
16. 10.1126/scitranslmed.aat880010.1126/scitranslmed.aat8800 ↗
17. 10.1016/j.joca.2015.07.01010.1016/j.joca.2015.07.010 ↗
18. 10.1007/s13238-017-0377-710.1007/s13238-017-0377-7 ↗
19. 10.1038/nmat211610.1038/nmat2116 ↗
20. 10.1016/j.jconrel.2018.12.02510.1016/j.jconrel.2018.12.025 ↗
21. 10.1186/ar460510.1186/ar4605 ↗
22. 10.1002/art.3796410.1002/art.37964 ↗
23. 10.3389/fimmu.2020.0001010.3389/fimmu.2020.00010 ↗
24. 10.1186/ar461310.1186/ar4613 ↗
25. 10.1136/annrheumdis-2020-21846910.1136/annrheumdis-2020-218469 ↗
26. 10.1016/j.biomaterials.2011.05.01710.1016/j.biomaterials.2011.05.017 ↗
27. 10.1021/acsami.0c1045810.1021/acsami.0c10458 ↗
28. 10.1038/gt.2015.1610.1038/gt.2015.16 ↗
29. 10.1016/j.biomaterials.2018.08.04510.1016/j.biomaterials.2018.08.045 ↗
30. 10.1016/j.colsurfb.2013.06.01510.1016/j.colsurfb.2013.06.015 ↗
31. 10.1007/s00281-017-0631-310.1007/s00281-017-0631-3 ↗
32. 10.1038/s41591-020-0939-810.1038/s41591-020-0939-8 ↗
33. 10.1038/nrrheum.2016.9110.1038/nrrheum.2016.91 ↗
34. 10.1038/nri209410.1038/nri2094 ↗
35. 10.1038/nrrheum.2016.6910.1038/nrrheum.2016.69 ↗
36. 10.2147/IJN.S14099210.2147/IJN.S140992 ↗
37. 10.1186/s12951-018-0382-x10.1186/s12951-018-0382-x ↗
38. 10.1039/D0NR00454E10.1039/D0NR00454E ↗
39. 10.1016/j.msec.2019.10976610.1016/j.msec.2019.109766 ↗
40. 10.1016/j.biomaterials.2017.03.04410.1016/j.biomaterials.2017.03.044 ↗
41. 10.1021/ar700081510.1021/ar7000815 ↗
42. Hu F. · Nat. Commun. · 2020 · 11
43. 10.1016/j.biomaterials.2020.12029610.1016/j.biomaterials.2020.120296 ↗
44. 10.1016/j.jconrel.2020.01.05410.1016/j.jconrel.2020.01.054 ↗
45. 10.1016/j.biomaterials.2020.12039010.1016/j.biomaterials.2020.120390 ↗
46. 10.1021/acsnano.8b0878510.1021/acsnano.8b08785 ↗
47. 10.1038/mt.2008.22010.1038/mt.2008.220 ↗
48. 10.1016/j.ymthe.2019.05.00210.1016/j.ymthe.2019.05.002 ↗
49. 10.1186/s13075-017-1303-310.1186/s13075-017-1303-3 ↗
50. Jay G. D. · J. Rheumatol. · 2000 · 27 · 594
51. 10.1038/s41584-020-0413-510.1038/s41584-020-0413-5 ↗
52. 10.1016/S1525-0016(03)00181-310.1016/S1525-0016(03)00181-3 ↗
53. 10.1111/jcmm.1354910.1111/jcmm.13549 ↗
54. 10.1016/j.bios.2015.09.04710.1016/j.bios.2015.09.047 ↗
55. Müller‐Ladner U. · J. Immunol. · 1997 · 158 · 349210.4049/jimmunol.158.7.3492 ↗
56. 10.1038/sj.gt.330101410.1038/sj.gt.3301014 ↗
57. 10.1023/A:101609290936510.1023/A:1016092909365 ↗
58. 10.1002/(SICI)1521-2254(200005/06)2:3<210::AID-JGM101>3.0.CO;2-P10.1002/(SICI)1521-2254(200005/06)2:3<210::AID-JGM101>3.0.CO;2-P ↗
59. 10.1002/1529-0131(199904)42:3<490::AID-ANR14>3.0.CO;2-L10.1002/1529-0131(199904)42:3<490::AID-ANR14>3.0.CO;2-L ↗
60. 10.1089/hum.2008.07510.1089/hum.2008.075 ↗
61. Hong S. S. · Nat. Commun. · 2017 · 8
62. 10.4049/jimmunol.180030410.4049/jimmunol.1800304 ↗
63. 10.1021/acsami.0c0984210.1021/acsami.0c09842 ↗
64. 10.1080/10717544.2018.144705010.1080/10717544.2018.1447050 ↗
65. 10.1016/j.autrev.2017.04.00510.1016/j.autrev.2017.04.005 ↗
66. 10.1073/pnas.110356910810.1073/pnas.1103569108 ↗
67. 10.1016/j.jconrel.2018.08.00710.1016/j.jconrel.2018.08.007 ↗
68. 10.1136/annrheumdis-2012-20145710.1136/annrheumdis-2012-201457 ↗
69. 10.1016/j.jaut.2019.05.01610.1016/j.jaut.2019.05.016 ↗
70. 10.1016/j.autrev.2009.12.01310.1016/j.autrev.2009.12.013 ↗
71. 10.1016/j.autrev.2018.06.00610.1016/j.autrev.2018.06.006 ↗
72. 10.1038/ncomms1425210.1038/ncomms14252 ↗
73. 10.1021/acs.molpharmaceut.0c0095410.1021/acs.molpharmaceut.0c00954 ↗
74. 10.1021/acs.bioconjchem.9b0051810.1021/acs.bioconjchem.9b00518 ↗
75. 10.1021/acsami.0c1946810.1021/acsami.0c19468 ↗
76. 10.1126/sciadv.aax796410.1126/sciadv.aax7964 ↗
77. Mello S. B. V. · Int. J. Nanomed. · 2013 · 8 · 443
78. 10.1073/pnas.130337711010.1073/pnas.1303377110 ↗
79. 10.1016/j.fct.2019.11095810.1016/j.fct.2019.110958 ↗
80. 10.1039/C9BM01384A10.1039/C9BM01384A ↗
81. 10.1073/pnas.160223011310.1073/pnas.1602230113 ↗
82. 10.1038/s41590-020-00816-x10.1038/s41590-020-00816-x ↗
83. 10.3389/fimmu.2019.0035310.3389/fimmu.2019.00353 ↗
84. 10.1016/j.molmed.2016.01.00510.1016/j.molmed.2016.01.005 ↗
85. Jhun J. · PLoS One · 2020 · 15
86. 10.1038/nrd379410.1038/nrd3794 ↗
87. 10.1136/annrheumdis-2016-20983110.1136/annrheumdis-2016-209831 ↗
88. 10.1038/nrrheum.2011.14510.1038/nrrheum.2011.145 ↗
89. 10.1002/adhm.20200157010.1002/adhm.202001570 ↗
90. 10.1016/j.intimp.2018.01.01010.1016/j.intimp.2018.01.010 ↗
91. 10.1002/art.4077310.1002/art.40773 ↗
92. 10.1002/jcb.2890110.1002/jcb.28901 ↗
93. 10.1136/annrheumdis-2020-21784410.1136/annrheumdis-2020-217844 ↗
94. 10.1111/imr.1282910.1111/imr.12829 ↗
95. 10.1016/j.mehy.2012.01.01010.1016/j.mehy.2012.01.010 ↗
96. 10.1136/annrheumdis-2012-20286810.1136/annrheumdis-2012-202868 ↗
97. 10.3390/ijms1901032610.3390/ijms19010326 ↗
98. Wu H. · Int. Immunopharmacol. · 2020 · 88
99. 10.1177/2632010X2095181210.1177/2632010X20951812 ↗
100. 10.1038/nature0165810.1038/nature01658 ↗